Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Vinblastine in Elderly cHL (NIVINIHO)
NCT03580408Phase 2Completed
- Sponsor
- LYSARC
- Start
- Aug 2018
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab in classical Hodgkin lymphoma (cHL), sponsored by LYSARC. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03580408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580408.